tirzepatide off label GLP-1 medications are not approved by the Food and Drug Administration to treat polyendocrine metabolic ovarian syndrome (PMOS), the condition renamed from polycystic ovary syndrome in 2026. Because the use is off-label Microdosing tirzepatide with multi‑dose Mounjaro

Veszelka S, Bocsik A, Walter FR, Hantosi D, Deli MA

Cellulite is most likely to appear in the fatty, fleshy areas of the body where the skin is farthest away from the bone

FAQ What are the potential side effects of tirzepatide

On This Page Indications and Usage Dosage and Administration Dosage Forms and Strengths Contraindications Warnings and Precautions Adverse Reactions/Side Effects Drug Interactions Use In Specific Populations Overdosage Description Clinical Pharmacology Nonclinical Toxicology Clinical Studies How Supplied/Storage and Handling Storage and Handling Patient Counseling Information Medication Guide Highlights of Prescribing Information MOUNJARO (tirzepatide) Injection, for subcutaneous use Initial U.S